Company profile

Opna Bio LLC

Privately held: no public share price (Clinical-stage oncology biopharmaceutical company (OPN-6602 dual EP300/CBP inhibitor for MM; zavabresib/OPN-2853 BET inhibitor), venture-funded ($38M Series A, led by Longitude Capital/Northpond Ventures). No public listing found. Source: opnabio.com, MTEC-SC.org. Sources: https://clinicaltrials.gov/study/NCT06433947 Entity resolved by asset-pipeline-v2.)

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
OPN-6602
Phase 1
CBP (CREB-binding protein) and EP300 (p300) bromodomainsSmall molecule
Multiple Myeloma

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.